Expression of PDE11A in normal and malignant human tissues

Journal of Histochemistry and Cytochemistry

Volumn 53, Issue 7, 2005, Pages 895-903

  D'Andrea, Michael R ^a   Qiu, Yuhong ^a   Haynes Johnson, Donna ^a   Bhattacharjee, Sheela ^a   Kraft, Patricia ^a   Lundeen, Scott ^a  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Immunohistochemistry; Normal and cancer human tissues; PDE11A; Tissue distribution

Indexed keywords

COMPLEMENTARY DNA; CYCLIC AMP; CYCLIC GMP; CYCLIC NUCLEOTIDE PHOSPHODIESTERASE; CYCLIC NUCLEOTIDE PHOSPHODIESTERASE 11A; DIPYRIDAMOLE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; ISOBUTYLMETHYLXANTHINE; MESSENGER RNA; MILRINONE; PHOSPHODIESTERASE I; PHOSPHODIESTERASE III; PHOSPHODIESTERASE III INHIBITOR; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE IV; PHOSPHODIESTERASE IV INHIBITOR; PHOSPHODIESTERASE V; PHOSPHODIESTERASE V INHIBITOR; POLYADENYLATED RNA; RECOMBINANT ENZYME; ROLIPRAM; SILDENAFIL; TRITIUM; UNCLASSIFIED DRUG; VINPOCETINE; ZAPRINAST;

ARTICLE; BREAST CARCINOMA; CELL TYPE; COLON CARCINOMA; CONTROLLED STUDY; ENZYME INHIBITION; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; LUNG CARCINOMA; MALE; MELANOMA; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN EXPRESSION; TISSUE DISTRIBUTION; WESTERN BLOTTING;

ENDOTHELIAL CELLS; EPITHELIAL CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; MYOCYTES, SMOOTH MUSCLE; NEOPLASMS; ORGAN SPECIFICITY; PHOSPHORIC DIESTER HYDROLASES;

EID: 21544469970     PISSN: 00221554     EISSN: None     Source Type: Journal    
DOI: 10.1369/jhc.5A6625.2005     Document Type: Article

References (30)

1. Bang YJ, Pirnia F, Fang WG, Kang WK, Sartor O, Whitesell L, Tsokos MJ, et al. (1994) Terminal neuroendocrine differentiation of human prostate carcinoma cells in response to increased intracellular cyclic AMP. Proc Natl Acad Sci USA 91:5330-5334
2. Beavo JA (1995) Cyclic nucleotide phosphodiesterases: functional implication of multiple isoforms. Physiol Rev 75:725-748
3. Bolger GB, McPhee I, Houslay MD (1996) Alternative splicing of cAMP-specific phosphodiesterase mRNA transcripts. Characterization of a novel tissue-specific isoform, RNPDE4A8. J Biol Chem 271:1065-1071
4. Boolell M, Allen MJ, Ballard SA, Gepi-Attee S, Muirhead GJ, Naylor AM, Osterloh IH, et al. (1996) Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int J Impot Res 8:47-52
5. Burnett AL, Lowenstein CJ, Bredt DS, Chang TS, Snyder SH (1992) Nitric oxide: a physiologic mediator for penile erection. Science 257:401-403
6. Chen TC, Wadsten P, Su S, Rawlinson N, Hofman FM, Hill CK, Schonthal AH (2002) The type IV phosphodiesterase inhibitor rolipram induces expression of the cell cycle inhibitors p21(Cip1) and p27(Kip1), resulting in growth inhibition, increased differentiation, and subsequent apoptosis of malignant A-172 glioma cells. Cancer Biol Ther 1:268-276
7. D'Andrea MR, Saban MR, Nguyen N-B, Andrade-Gordon P, Saban R (2003) Overriding participation of protease activated receptor (PAR)s 1, 2, 3, and 4 in experimental bladder inflammation. Am J Pathol 162:907-923
8. Diab-Assef M, Reimund JM, Ezenfis J, Duclos B, Kedinger M, Flotzer-Jourdainne C (2002) The phosphodiesterase inhibitor, pentoxifylline, alters rat intestinal epithelial cell proliferation via changes in the expression of transforming growth factors. Scand J Gastroenterol 37:206-214
9. Eardley I (1997) The role of phosphodiesterase inhibitors in impotence. Expert Opin Investig Drugs 6:1803-1810
10. Fawcett L, Baxendale R, Stacey P, McGrouther C, Harrow I, Soderling S, Hetman J, et al. (2000) Molecular cloning and characterization of a distinct human phosphodiesterase gene family: PDE11A. Proc Natl Acad Sci USA 97:3702-3707
11. Francis SH, Turko PV, Corbin JD (2001) Cyclic nucleotide phosphodiesterases: relating structure and function. Prog Nucleic Acid Res Mol Biol 65:1-52
12. Goto T, Matsushima H, Kasuya Y, Hosaka Y, Kitamura T, Kawabe K, Hida A, et al. (1999) The effect of papaverine on morphologic differentiation, proliferation and invasive potential of human prostatic cancer LNCaP cells. Int J Urol 6:314-319
13. Guh JH, Hwang TL, Ko FN, Chueh AC, Lai MK, Teng CM (1998) Antiproliferative effect in human prostatic smooth muscle cells by nitric oxide donor. Mol Pharmacol 53:467-474
14. Guillemin MC, Raffoux E, Vitoux D, Kogan S, Soilihi H, Lallemand-Breitenbach V, Zhu J, et al. (2002) In vivo activation of cAMP signaling induces growth arrest and differentiation in acute promyelocytic leukemia. J Exp Med 196:1373-1380
15. Hetman JA, Robas N, Baxendale R, Fidock M, Phillips SC, Soderling SH, Beavo JA (2000) Cloning and characterization of two splicing variants of human phosphodiesterase 11A. Proc Natl Acad Sci USA 97:12891-12895
16. Hirsh L, Dantes A, Suh BS, Yoshida Y, Kumiko H, Tajima K, Kotsuji F, et al. (2004) Phosphodiesterase inhibitors as anti-cancer drugs. Biochem Pharmacol 68:981-988
17. Hofmann F, Ammendola A, Schlossmann J (2000) Rising behind NO: cGMP-dependent protein kinases. J Cell Sci 113:1671-1676
18. Maggi M, Filippi S, Ledda F, Magini A, Forti G (2000) Erectile dysfunction: from biochemical pharmacology to advances in medical therapy. Eur J Endocrinol 143:143-154
19. Maurice DH, Palmer D, Tilley DG, Dunkerley HA, Netherton SJ, Raymond DR, Elbatarny HS, et al. (2003) Cyclic nucleotide phosphodiesterase activity, expression and targeting in cells of the cardiovascular system. Mol Pharmacol 64:533-546
20. O'Grady SM, Jiang X, Maniak PJ, Birmachu W, Scribner LR, Bulbulian B, Gullikson GW (2002) Cyclic AMP-dependent Cl secretion is regulated by multiple phosphodiesterase subtypes in human colonic epithelial cells. J Membr Biol 185:137-144
21. Qiu Y, Bhattacharjee S, Kraft P, John TM, Craig E, Haynes-Johnson D, Guan J, et al. (2003) Characterization of a novel phosphodiesterase type 5 inhibitor: JNJ-10258859. Eur J Pharmacol 472:73-80
22. Rybalkin SD, Bornfeldt KE (1999) Cyclic nucleotide phosphodiesterases and human arterial smooth muscle cell proliferation. Thromb Haemost 82:424-434
23. Rybalkin SD, Yan C, Bornfeldt KE, Beavo JA (2003) Cyclic GMP phosphodiesterases and regulation of smooth muscle function. Circ Res 93:280-291
24. Sasaki K, Manabe H (2004) KF19514, a phosphodiesterase 4 and 1 inhibitor, inhibits TNF-α-induced GM-CSF production by a human bronchial epithelial cell line via inhibition of PDE4. Inflamm Res 53:31-37
25. Shafer SH, Phelps SH, Williams CL (1998) Reduced DNA synthesis and cell viability in small cell lung carcinoma by treatment with cyclic AMP phosphodiesterase inhibitors. Biochem Pharmacol 56: 1229-1236
26. Torphy TJ, Undem BJ, Cieslinski LB, Luttmann MA, Reeves ML, Hay DWP (1993) Identification, characterization and functional role of phosphodiesterase isozymes in human airway smooth muscle. J Pharm Exp Ther 265:1213-1223
27. Wallis RM, Corbin JD, Francis SH, Ellis P (1999) Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro. Am J Cardiol 83:3C-12C
28. Yan C, Zhao AZ, Bentley JK, Beavo JA (1996) The calmodulin-dependent phosphodiesterase gene PDE1C encodes several functionally different splice variants in a tissue-specific manner. J Biol Chem 271:25699-25706
29. Yuasa K, Kotera J, Fujishige K, Michibata H, Sasaki T, Omori K (2000) Isolation and characterization of two novel phosphodiesterase PDE11A variants showing unique structure and tissue-specific expression. J Biol Chem 275:31469-31479
30. Yuasa K, Ohgaru T, Asahina M, Omori K (2001) Identification of rat cyclic nucleotide phosphodiesterase 11A (PDE11A)-comparison of rat and human PDE11A splicing variants. Eur J Biochem 268:4440-4448